Exatecan Intermediate 1

• Description :

  Exatecan Intermediate 1 (compound 6) is an intermediate of Exatecan (HY-13631) . Exatecan is a DNA topoisomerase I inhibitor with anticancer effects[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  ADC Payload; Topoisomerase

• Type :

  Reference compound

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/exatecan-intermediate-1.html

• Purity :

  99.99

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  O=C1[C@](O)(CC)C(C=C23)=C(CO1)C(N3CCC2=O)=O

• Molecular Formula :

  C13H13NO5

• Molecular Weight :

  263.25

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Weng W, et al. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov. 2023 Apr 3;13 (4) :950-973. |[2]Zhang Hongwei, et al. Intermediate for synthesizing camptothecin derivatives using exatecan mesylate and its preparation method and application. China, CN111470998. 2020-07-31. |[3]Conilh L, et al. Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals (Basel) . 2021 Mar 9;14 (3) :247.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Camptothecins

• CAS Number :

  [110351-94-5]